OncoHost

09/22/2026

Our WCLC 2026 research continues to generate important discussion!

In a new OncLive interview, David R. Gandara, MD, co-author of the study and co-presenter of OncoHost’s poster at WCLC 2026, discusses the findings and the opportunity to expand beyond PD-L1 alone through plasma proteomics and PROphetNSCLC®.

Read the article and watch the interview:
https://www.onclive.com/view/dr-gandara-on-expanding-beyond-pd-l1-as-a-biomarker-in-nsclc

David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.

07/13/2026

📍 Headed to the New Orleans Summer Cancer Meeting (NOSCM) this week?

Meet Kevin Prophete, our Regional Sales Director, and learn how our AI-powered PROphet® platform is helping oncologists personalize immunotherapy with confidence.

📅 July 17–19, 2026

We’re looking forward to connecting!

06/25/2026

Missed Technology Networks 'The Landscape of Cancer Research: Advances in Immuno-Oncology 2026' online symposium?

You can still catch our CEO, Ofer Sharon,MD, presenting:
"Beyond Tumor-Centric Precision: Why Host-Response Biology Is Redefining Immuno-Oncology Decision-Making."

As immuno-oncology continues to evolve, it's becoming increasingly clear that tumor characteristics alone don't tell the full story.
In this session, Ofer explores:
🔹 Why host-response biology is emerging as a critical component of precision immuno-oncology
🔹 How large-scale plasma proteomics can provide actionable insights into immune regulation, inflammation, and tumor-host interactions
🔹 Why biology-driven biomarkers can help enable more confident first-line treatment decisions and reduce ineffective therapies

Watch the on-demand session here:
https://www.bigmarker.com/labx-media-group/day-2-the-landscape-of-cancer-research-advances-in-immuno-oncology-2026?bmid=8f5a67ec94e5&bma=2877ebf9a3f1&bmi=c6534f41ff46&bmid_type=member

As demand for reliable and sustainable energy production and storage continues to grow, this event will provide a platform to explore the latest developments in battery innovation.

06/09/2026

What an incredible experience at in Budapest!

It was a privilege for our CTO, Dr. Yehonatan Elon, to join leading researchers, clinicians, and innovators from around the world to discuss how plasma proteomics and AI are transforming the future of precision oncology.

Thank you to everyone who attended the session, shared insights, and contributed to the meaningful conversations throughout the conference. The engagement and enthusiasm around the potential of data-driven cancer care were truly inspiring 💡

A special thank you to Illumina and SomaLogic for making this opportunity possible and for their continued commitment to advancing cancer research through innovation. 🙏

06/03/2026

How can plasma proteomics and AI help redefine precision oncology research?

Join our CTO, Dr. Yehonatan Elon, at European Association for Cancer Research (EACR)2026in Budapest as he discusses how advanced proteomic profiling combined with artificial intelligence is driving a new era of personalized cancer care.

We're proud to contribute to the conversation alongside leaders in cancer research and innovation, and grateful to Illumina and SomaLogic for supporting this important discussion.@
📍 Budapest, Hungary
📅 8June 2026

05/27/2026

We’re excited to connect with you at the upcoming Annual Meeting in Chicago!

📍 Visit Us at Booth #28148
Stop by to meet our leadership team and explore how our proteomics and AI-powered platform is driving the next era of precision oncology.

05/11/2026

Our team is gearing up for ASCO 2026!
Stop by our booth #28148 or reach out to [email protected] to set up a meeting!

05/04/2026

May is National Cancer Research Month, an initiative led by the American Association for Cancer Research (AACR) to highlight the critical importance of life-saving research for the millions of people worldwide affected by cancer.

04/24/2026

🔬 It’s Medical Laboratory Professionals Week!

Here’s to the brilliant minds working behind the scenes to power precision medicine and patient care.
Thank you to our incredible lab professionals - Jim Fuller, Amir Gelman, Michael Hoxie & Macalla Tate! Your dedication to accuracy and excellence is what enables innovation to reach each patient.

04/23/2026

Our Chief Commercial Officer, Chris Dingman, took the stage to present our latest poster, highlighting the role of biological aging in predicting outcomes. The work underscores our ongoing commitment to equipping physicians with tools that bring greater clarity to complex clinical choices.

Take a closer look at the science driving the future of personalized cancer care.